Triple-Drug cocktail targets Hard-to-Treat colorectal cancer

This study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with a type of advanced colorectal cancer that has not responded to prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive the drugs and are monitored with scans and lab tests. The study is small (13 people) and in phase 2, so results will show if this approach is promising enough for larger trials.